A Dehydration–Diffusion Competition Framework Predicts Interfacial Film Risk in High-Concentration Biologics Fill-Finish
High-concentration protein formulations are increasingly demanded for the development of subcutaneous injections owing to its clinical and commercial advantages. However, their high protein concentrations can lead to dried residues, causing failures in manufacturing operations such as piston pump seizing and filling needle clogging. Transient dehydration during fill-finish holds can generate interfacial viscoelastic films that resist redissolution and perturb delivery performance. Here, we establish an operational framework that links dehydration exposure to film mechanics and reversibility for high-concentration biologics. Using a bench-scale apparatus with controlled airflow, we observe orders-of-magnitude increases in interfacial storage modulus (<i>G</i>') with accumulated mass loss (<i>m</i>) and identify conditions where films fail to fully redissolve on minutes time scales. We define four portable readouts, maximum film strength (<i>G</i><sub>M</sub><sup>'</sup>), final film strength (<i>G</i><sub>F</sub><sup>'</sup>), imbibition time (<i>t</i><sub>Imb</sub>), and dissolving time (<i>t</i><sub>Dis</sub>)─to translate viscoelastic traces into process decision variables. Normalization by hydrodynamic volume fraction (ϕ<sub>hyd</sub>) exposes two packing thresholds that organize mechanics and kinetics: a transition near random loose packing (RLP, ϕ<sub>RLP</sub> ≈0.56), where percolation limits rearrangement and attenuates growth of <i>G</i><sub>M</sub><sup>'</sup>, and a second near random close packing (RCP, ϕ<sub>RCP</sub> ≈0.64), where bulk jamming undercuts further strengthening and slows film disintegration. Consistently, <i>t</i><sub>Imb</sub> steeply scales once mass loss approaches ∼30% (mapping toward RCP), while <i>t</i><sub>Dis</sub> reflects a protein diffusion-dominated recovery. A critical ∼52-55% mass-loss window marks a sharp rise in <i>G</i><sub>F</sub><sup>'</sup> and elastic persistence (<i>G</i>' > <i>G</i>″) after imbibition, indicating conditional irreversibility on process time scales. Together, these results yield an actionable "no-film/at-risk" map indexed to exposure dehydration flux, time, and formulation, providing quantitative limits for downtime and rewet strategies in fill-finish.
Authors
- Adam Procopio (ORCID: https://orcid.org/0000-0002-6786-0764)
- Wei Xu (ORCID: https://orcid.org/0000-0003-3460-0330)
- Hanmi Xi (ORCID: https://orcid.org/0000-0002-5102-792X)
- Iriny Ekladious (ORCID: https://orcid.org/0000-0003-1192-1414)
- Katelyn Smith
- Qi Gao (ORCID: https://orcid.org/0000-0001-5425-2471)
- Mark A. McCoy (ORCID: https://orcid.org/0000-0003-3994-6605)
- Yu‐Jiun Lin (ORCID: https://orcid.org/0000-0002-0655-9580)
- Ruomeng Qiu (ORCID: https://orcid.org/0000-0001-7916-1509)
- Yu Tian (ORCID: https://orcid.org/0000-0002-0253-6883)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Clinical Science Institute (US)
Publication Details
- Journal
- Molecular Pharmaceutics
- Published
- 2025-11-16
- DOI
- https://doi.org/10.1021/acs.molpharmaceut.5c01406
- Citations
- 1
- Primary Topic
- Protein purification and stability
- Type
- article
- Field-Weighted Citation Impact
- 0.81